Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain
Andreu Altés, Óscar Moreno-Pérez, Miquel Sastre-Belío, Ened Rodríguez-Urgellés, Ferran Pérez-Alcántara, Sara Larsen, Alberto Martín-Lorenzo, Miriam Sandín, Josep Vidal · 2026
Read Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain by Andreu Altés, Óscar Moreno-Pérez, Miquel Sastre-Belío, Ened Rodríguez-Urgellés, Ferran Pérez-Alcántara, Sara Larsen, Alberto Martín-Lorenzo, Miriam Sandín, Josep Vidal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13499823.txt.
Description
Altés and co-authors ask whether Spain's health service gets its money's worth from semaglutide injections for obesity. Their 2026 economic model took effectiveness data from the STEP 1 trial. It projected costs and health over forty years, comparing the injection plus diet and exercise support against lifestyle support alone. Benefits were counted in quality-adjusted life years, which combine length and quality of life.
Adding semaglutide bought a modest extra slice of healthy life per person while raising lifetime healthcare costs by a few thousand euros. That produced a cost per healthy year in the mid twenty-thousands of euros. The figure sat below the thirty-thousand-euro threshold the authors use for value, and stress tests never pushed it above the line. They conclude the drug is cost-effective for Spain under current assumptions, driven largely by avoided diabetes and cardiovascular disease.
Catalog record
| CREATOR | Andreu Altés, Óscar Moreno-Pérez, Miquel Sastre-Belío, Ened Rodríguez-Urgellés, Ferran Pérez-Alcántara, Sara Larsen, Alberto Martín-Lorenzo, Miriam Sandín, Josep Vidal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |